Management
David Deems
President, Diagnostics
David Deems joined Xceed Molecular (now part of Axela) from Predicant Biosciences, an early stage proteomics company working to identify protein patterns in blood for the early detection of cancer. At Predicant, David was Vice President of Development and Operations, responsible for managing Predicant’s product and commercial development efforts. Prior to Predicant, David has held senior management positions with several companies focused on bringing novel products successfully into the marketplace, including as Vice President of Product Development at EXACT Sciences, CEO of Union Biometrica, prior to that company’s acquisition by Harvard Biosciences, and Vice President at BD Biosciences, a division of Becton, Dickinson and Company. David is also a co-founder of Cephos Corporation, an early stage company focused on the use of functional magnetic resonance imaging for deception detection.